65818-01-1 Usage
Uses
Used in Pharmaceutical Industry:
4H-Cyclopentapyrimidin-4-one, 3,5,6,7-tetrahydro-2-methyl(9CI) is used as a pharmaceutical intermediate for the development of new drugs. Its heterocyclic structure allows for the modulation of specific biological pathways, offering potential therapeutic benefits in various medical conditions.
Used in Drug Design and Synthesis:
4H-Cyclopentapyrimidin-4-one, 3,5,6,7-tetrahydro-2-methyl(9CI) serves as a key building block in the design and synthesis of novel pharmaceutical agents. Its unique cyclopentapyrimidinone core and tetrahydro-2-methyl substituents provide a versatile scaffold for chemical modifications, enabling the creation of diverse drug candidates with tailored properties and improved efficacy.
Used in Medicinal Chemistry Research:
4H-Cyclopentapyrimidin-4-one, 3,5,6,7-tetrahydro-2-methyl(9CI) is utilized in medicinal chemistry research to study the structure-activity relationships of heterocyclic compounds. Understanding how its molecular features influence biological activity can guide the optimization of drug candidates and the discovery of new therapeutic agents.
Used in Drug Discovery and Development:
4H-Cyclopentapyrimidin-4-one, 3,5,6,7-tetrahydro-2-methyl(9CI) plays a crucial role in drug discovery and development processes, where its heterocyclic structure can be exploited to identify potential lead compounds with novel mechanisms of action. Its exploration can lead to the development of innovative treatments for various diseases and conditions, enhancing the therapeutic arsenal available to healthcare professionals.
Check Digit Verification of cas no
The CAS Registry Mumber 65818-01-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,5,8,1 and 8 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 65818-01:
(7*6)+(6*5)+(5*8)+(4*1)+(3*8)+(2*0)+(1*1)=141
141 % 10 = 1
So 65818-01-1 is a valid CAS Registry Number.
65818-01-1Relevant articles and documents
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer
Yang, Zhuang,Wang, Taijin,Wang, Fang,Niu, Ting,Liu, Zhuowei,Chen, Xiaoxin,Long, Chaofeng,Tang, Minghai,Cao, Dong,Wang, Xiaoyan,Xiang, Wei,Yi, Yuyao,Ma, Liang,You, Jingsong,Chen, Lijuan
, p. 1455 - 1470 (2016/03/08)
Novel selective histone deacetylase 6 (HDAC6) inhibitors using the quinazoline as the cap were designed, synthesized, and evaluated for HDAC enzymatic assays. N-Hydroxy-4-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)butanamide, 23bb, was the
Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents
Gangjee, Aleem,Zhao, Ying,Raghavan, Sudhir,Rohena, Cristina C.,Mooberry, Susan L.,Hamel, Ernest
, p. 6829 - 6844 (2013/10/01)
A series of 21 substituted cyclopenta[d]pyrimidines were synthesized as an extension of our discovery of the parent compound (±)-1·HCl as an anti-microtubule agent. The structure-activity relationship indicates that the N-methyl and a 4N-methoxy groups appear important for potent activity. In addition, the 6-substituent in the parent analogue is not necessary for activity. The most potent compound 30·HCl was a one to two digit nanomolar inhibitor of most tumor cell proliferations and was up to 7-fold more potent than the parent compound (±)-1·HCl. In addition, 30·HCl inhibited cancer cell proliferation regardless of Pgp or βIII-tubulin status, both of which are known to cause clinical resistance to several anti-tubulin agents. In vivo efficacy of 30·HCl was demonstrated against a triple negative breast cancer xenograft mouse model. Compound 30·HCl is water-soluble and easily synthesized and serves as a lead compound for further preclinical evaluation as an antitumor agent.
